Asset profile
diranersen · Biogen (BIIB)
- Indication
- early Alzheimer's disease
- Also known as
- BIIB080, IONIS-MAPT Rx
Company
BIIBBiogen
BIIBBiogenBiogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates si…
On the calendar
Nothing scheduled in this window.
Timeline
Newest first.
Decision-grade
May 14, 2026
10:59 AM
BIIBBiogenRegistered trials
| Registry ID | Phase | Status | Primary completion | Enrollment | Sites |
|---|---|---|---|---|---|
| NCT05399888 | Phase 2 | Active, not recruiting | Mar 11, 2026 | 416 | 36 of 138 sites in the United States |
More from Biogen
Other drugs and candidates from the same company tracked in this sector.